Table 5.

Entotic-CIC in PDAC and patient outcome (univariate analysis).

Factor			P value	Hazard ratio (95% confidence interval)
Clinicopathologic	Entotic-CIC	(Positive vs. negative)	<0.001	1.813 (1.323–2.484)
	Age	(>65 vs. < =65)	0.853	1.024 (0.8–1.31)
	Gender	(Male vs. female)	0.010	1.380 (1.082–1.761)
	Location	(Primary vs. metastasis)	<0.001	0.327 (0–0.423)
	Histology	(PDA vs. ASQ)	0.415	0.778 (0.425–1.424)
Genetic	KRAS	(Mutated vs. WT)	0.969	0.991 (0.646–1.521)
	TP53	(Mutated vs. WT)	0.173	1.216 (0.918–1.611)
	CDKN2A	(Mutated vs. WT)	0.094	1.259 (0.962–1.649)
	SMAD4	(Mutated vs. WT)	0.976	0.996 (0.746–1.329)
	CDKN2AP16INK4A	(Mutated vs. WT)	0.384	1.141 (0.848–1.534)
	ARID1A	(Mutated vs. WT)	0.395	1.179 (0.807–1.725)
	CDKN2AP14ARF	(Mutated vs. WT)	0.310	1.199 (0.844–1.703)
	RNF43	(Mutated vs. WT)	0.382	0.772 (0.433–1.378)
	KDM6A	(Mutated vs. WT)	0.828	1.062 (0.619–1.82)
	APC	(Mutated vs. WT)	0.166	1.464 (0.854–2.51)
CNA alteration	MYC	(Amplified vs. not amplified)	0.883	0.941 (0.419–2.115)
	AKT2	(Amplified vs. not amplified)	0.399	1.297 (0.709–2.371)
	CCNE1	(Amplified vs. not amplified)	0.503	0.678 (0.217–2.116)
	KRAS	(Amplified vs. not amplified)	<0.001	5.480 (2.419–12.416)
	FGFR1	(Amplified vs. not amplified)	0.117	2.490 (0.796–7.788)
	CDKN2A	(Deep deletion vs. no deletion)	0.010	1.631 (1.122–2.372)
	CDKN2AP16INK4A	(Deep deletion vs. no deletion)	0.019	1.575 (1.077–2.303)
	CDKN2AP14ARF	(Deep deletion vs. no deletion)	0.016	1.604 (1.091–2.358)
	CDKN2B	(Deep deletion vs. no deletion)	0.216	1.291 (0.862–1.934)
	SMAD4	(Deep deletion vs. no deletion)	0.242	0.639 (0.302–1.353)

The bold value means statistically significant P value.